The dummy-run showed that the most significant deviations were obtained when ROs did not precisely apply the CG. Such systematic deviations in the contouring could have a dosimetric impact both for target coverage and OAR sparing, especially for particle therapy. The ROs were provided with the developed graphical tool in order to easily identify their deviations and take corrective actions. The graphical tool could also be useful for the optimization of the contouring strategies within individual Institutes.
Purpose or Objective:
To evaluate the role of adjuvant androgen deprivation therapy (ADT) in combination with postoperative radiotherapy (PORT) on biochemical-relapsefree-survival (b-NED) and metastatic-progression-free-survival (mts-NED) in high risk prostate cancer patients (pts).
Material and Methods:
Between 2004 and 2012 370 high risk prostate cancer pts received PORT : 120 pts had stage pT3a pN0, 150 pts pT3b pN0 , 100 pts pT2c/pT3 R1 and post surgical PSA > 0.2 ng/ml detected in 50 pts. Mean age was 72 years (55-78 yrs). PORT on pelvis and surgical bed was delivered in 150 pts while 220 pts were treated on surgical bed . Dose to pelvis was 45-50 Gy, while dose on surgical bed was 66-72 Gy. ADT was administerd in 250 pts and consisted of LH-RH analog in monotherapy (70 pts), BAT (60 pts) and bicalutamide 150 mg (120 pts). Timing of ADT ranged six months to 3 years. ADT was administered during and after PORT with a median of 35 months. Kaplan-Mayer b-Ned and mts-Ned survivals , X-square (p< 0.05) and paired t-test for univariate and multivariate analyses (p< 0.001) were calculated.
Results: Three -hundred were evaluable at 64 months with a median of 5 years. Two groups were identified: ADT (210 pts) and no ADT (90 pts). One-hundred and twenty pts (120) relapsed: 40 pts in the no ADT group (5 with a biochemical relapse and 35 pts with a metastatic relapse) and 70 pts in the ADT group (20 pts with a biochemical relapse and 50 pts with a metastatic). The 5-year biochemical relapse free survival was 80% for ADT group and 78% for no ADT group (p = 0.34); the 5-year metastatatic progression free survival for ADT group was 82 % vs 65% (p< 0.05)for no ADT group. In the ADT group, radiotherapy dose <70 Gy and PSA >0.2 ng/ml were indipendent factors related to high risk of biochemicalrelapse while metastatic-relapse-free-survival was influenced by primary component 5 of the Gleason Score (GS) , no use of LH-RH analog and time of ADT<2aa . In the no ADT group, PSA > 0.2 ng/ml, radiotherapy dose <70 Gy and R1 disease, were factors influencing the biochemical relapse, while metastastic relapse was influenced by a value of 5 in the Gleason Score.
Conclusion:
The role of ADT in adjuvant setting prostate cancer is still unclear; our results suggest a benefit of ADT in metastatic-progression-free-survival, especially in case of primary component 5 in the GS , post-operative PSA >0, BAT<2 years.
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Long term patient reported urinary function following external beam radiotherapy for prostate cancer S. Chin Results: For patients with mild (48%), moderate (40%) and severe (12%) baseline total IPSS, median IPSS at baseline was 3,12, and 24. Median IPSS was 4, 9, and 12 at 6 months and 3, 9 and 14 at 48 months respectively. Late grade 2 genitourinary toxicity incidence was 7%, 20% and 33% and late grade 3 genitourinary toxicity was 1%, 2% and 1% respectively. At 48 months, 80%, 49% and 16% of patient with baseline mild, moderate and severe IPSS respectively demonstrated stable IPSS, 5%, 39% and 72% reported improving IPSS ≥5, and 14%, 12% and 6% had a worsening IPSS ≥5. 82% of patients with mild baseline IPSS had mild IPSS scores. 95% of patients with moderate baseline IPSS had mild or moderate IPSS scores, with 43% improving to mild IPSS scores. 75% of patients with severe baseline IPSS scores had improved to mild (28%) or moderate (47%) IPSS scores. 68% of the cohort reported good baseline urinary QoL (score 0-2), with 89% of these patients maintaining good urinary QoL at 48 months. 71% of patients with poor baseline urinary QoL (score 3-6) had improved to good urinary QoL.
Conclusion:
The majority of men undergoing definitive radiotherapy for prostate cancer report stable or improving late urinary symptom burden and urinary quality of life, even with severe urinary symptoms or poor urinary quality of life at baseline.
